Fast Track Initiative
Overview
Fast Track Initiative (FTI) is a healthcare-focused venture capital firm that operates in Japan and the United States. Established over 18 years ago, the firm has become a pioneer of healthcare venture investments in Japan. FTI primarily focuses its investments on early-stage life science startups, with the aim of growing seed and early-stage companies across a broad range of healthcare sectors, including therapeutics, diagnostics, digital health, and healthcare services, with a strong focus on therapeutic platforms. FTI provides hands-on operational support to its portfolio companies, helping them navigate the challenges of business and R&D strategy, strategic partnerships, investor syndication, and management recruitment.
Investments
| Company | Date | Stage | Lead |
|---|---|---|---|
| Storm Therapeutics | Apr 2026 | Series C | Co-investor |
| SONIRE Therapeutics Inc. | Apr 2026 | Series A | Co-investor |
| イチロウ株式会社 | Sep 2025 | Series B | Lead |
| Global Vascular Co., Ltd. | Jun 2025 | Series B | Co-investor |
| AIRNA | Apr 2025 | Series B | Co-investor |
Key People
Natalie Roy D'Amore
Venture Partner
Yukihiko Ebisuno
Venture Partner
Tai Harada
Partner
Tomohiro Anzai
COO And Managing Partner
Hiroko Kimura
Principal
Koji Yasuda
Principal
Sector & Stage Mix
Industry, funding stage, and valuation band breakdowns.
